The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Open accessAbstract
Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have been advanced to explain DOX cardiac side effects, which culminate in the development of life‐threatening cardiomyopathy. One of the most studied mechanisms involves the activation of DOX molecule into a more reactive semiquinone by mitochondrial Complex I, resulting in increased oxidative stress. The present review describes and critically discusses what is known about some of the potential mechanisms of DOX‐induced cardiotoxicity including mitochondrial oxidative damage and loss of cardiomyocytes. We also discuss alterations of mitochondrial metabolism and the unique characteristics of DOX delayed toxicity, which can also interfere on how the cardiac muscle handles a “second‐hit stress.” We also present pharmaceutical and nonpharmaceutical approaches that may decrease DOX cardiac alterations in animal models and humans and discuss the limitations of each strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Suliman, H. B., Carraway, M. S., Ali, A. S., Reynolds, C. M., Welty-Wolf, K. E., & Piantadosi, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32967 · Cited by 257
RetractedMinotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Ichijo, H., Nishida, E., Irie, K., Dijke, P. T., Saitoh, M., Moriguchi, T., Takagi, M., Matsumoto, K., Miyazono, K., & Gotoh, Y. (1997) · Science · doi:10.1126/science.275.5296.90 · Cited by 2,307
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Thompson, P. D., Buchner, D., Piña, I. L., Balady, G. J., Williams, M. A., Marcus, B. H., Berra, K., Blair, S. N., Costa, F., Franklin, B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000075572.40158.77 · Cited by 2,132
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,854
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635
A clinicopathologic analysis of adriamycin cardiotoxicity
Lefrak, E. A., Piťha, J., Rosenheim, S., & Gottlieb, J. A. (1973) · Cancer · doi:10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2 · Cited by 1,560
Doxorubicin: The good, the bad and the ugly effect
Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509 · cited 9×
“Biochem Biophys Res Commun 2009;378(3):450–455.”
BackgroundInfluentialSelf-citationRadical-free biology of oxidative stress
Jones, D. P. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00283.2008 · Cited by 1,213
Adriamycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response
Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K., & Young, R. C. (1977) · Science · doi:10.1126/science.877547 · Cited by 1,111
The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore
Kokoszka, J. E., Waymire, K. G., Levy, S. E., Sligh, J. E., Cai, J., Jones, D. P., MacGregor, G. R., & Wallace, D. C. (2004) · Nature · doi:10.1038/nature02229 · Cited by 1,086
Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2010) · Cardiology · doi:10.1159/000265166 · Cited by 1,065
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death
Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J., & Molkentin, J. D. (2007) · Nature Cell Biology · doi:10.1038/ncb1575 · Cited by 971
What is the mitochondrial permeability transition pore?
Halestrap, A. P. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.02.021 · Cited by 933
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis
Vaseva, A. V., Marchenko, N. D., Ji, K., Tsirka, S. E., Holzmann, S., & Moll, U. M. (2012) · Cell · doi:10.1016/j.cell.2012.05.014 · Cited by 740
Cardiotoxicity of Chemotherapeutic Agents: Incidence, Treatment and Prevention
Pai, V. B., & Nahata, M. C. (2000) · Drug Safety · doi:10.2165/00002018-200022040-00002 · Cited by 729
Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Broekemeier, K. M., Dempsey, M. E., & Pfeiffer, D. R. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83116-7 · Cited by 699
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow, J. H. (1983) · PubMed · Cited by 629
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Halestrap, A. P., Woodfield, K.-Y., & Connern, C. P. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3346 · Cited by 590
Anthracycline cardiomyopathy monitored by morphologic changes.
Billingham, M. E., Mason, J. W., Bristow, M. R., & Daniels, J. R. (1978) · PubMed · Cited by 586
Mitochondrial permeability transition in Ca2+-dependent apoptosis and necrosis
Rasola, A., & Bernardi, P. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.04.007 · Cited by 563
Doroshow, J. H., & Davies, K. J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35747-2 · Cited by 540
Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography
Alexander, J., Dainiak, N., Berger, H. J., Goldman, L., Johnstone, D., Reduto, L., Duffy, T., Schwartz, P., Gottschalk, A., Zaret, B. L., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197902083000603 · Cited by 535
Childs, A. C., Phaneuf, S., Dirks, A. J., Phillips, T., & Leeuwenburgh, C. (2002) · PubMed · Cited by 525
Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis.
Arola, O., Saraste, A., Pulkki, K. J., Kallajoki, M. A., Parvinen, M., & Voipio-Pulkki, L. M. (2000) · PubMed · Cited by 494
Carnitine and Acylcarnitines: Pharmacokinetic, Pharmacological and Clinical Aspects
Reuter, S. E., & Evans, A. M. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261931 · Cited by 493
Cysteine/cystine redox signaling in cardiovascular disease
Go, Y.-M., & Jones, D. P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.029 · Cited by 447
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Adriamycin-induced oxidative mitochondrial cardiotoxicity
Berthiaume, J. M., & Wallace, K. B. (2007) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0140-y · Cited by 409
Doxorubicin‐Induced Cardiac Mitochondrionopathy
Wallace, K. B. (2003) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2003.930301.x · Cited by 389
Cardiomyocyte death in doxorubicin-induced cardiotoxicity
Zhang, Y.-W., Shi, J., Li, Y.-J., & Wei, L. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0051-8 · Cited by 387
Mukhopadhyay, P., Rajesh, M., Bátkai, S., Kashiwaya, Y., Haskó, G., Liaudet, L., Szabó, C., & Pacher, P. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00795.2008 · Cited by 376
Kotamraju, S., Konorev, E. A., Joseph, J., & Kalyanaraman, B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003890200 · Cited by 372
McSTAY, G. P., CLARKE, S. J., & HALESTRAP, A. P. (2002) · Biochemical Journal · doi:10.1042/bj20011672 · Cited by 367
Endothelial Nitric Oxide Synthase-Dependent Superoxide Generation from Adriamycin
Vásquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S. S., Pritchard, & Kalyanaraman, B. (1997) · Biochemistry · doi:10.1021/bi971475e · Cited by 366
Antioxidant nutrients and adriamycin toxicity
Quiles, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00383-9 · Cited by 362
The role of the mitochondrial permeability transition pore in heart disease
Halestrap, A. P., & Pasdois, P. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.12.017 · Cited by 362
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
The complexity of cardiolipin in health and disease
Claypool, S. M., & Koehler, C. M. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.09.003 · Cited by 345
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5841 · Cited by 335
Leung, A. W. C., Varanyuwatana, P., & Halestrap, A. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805235200 · Cited by 314
Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin.
Zhou, S., Starkov, A. A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001) · PubMed · Cited by 314
Adriamycin cardiomyopathy: pathophysiology and prevention
Singal, P. K., Iliskovic, N., Li, T., & Kumar, D. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.12.9337145 · Cited by 310
Kang, Y. J., Chen, Y., & Epstein, P. N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12610 · Cited by 303
Early and delayed clinical cardiotoxicity of doxorubicin
Buzdar, A. U., Marcus, C., Blumenschein, G. R., & Smith, T. L. (1985) · Cancer · doi:10.1002/1097-0142(19850615)55:12<2761::aid-cncr2820551206>3.0.co;2-p · Cited by 300
Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., & Patrone, F. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.024 · Cited by 294
Doroshow, J. H. (1983) · PubMed · Cited by 282
The mitochondrial permeability transition pore and ischemia-reperfusion injury
Baines, C. P. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0004-8 · Cited by 280
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).
Bonadonna, G., Monfardini, S., Lena, M. D., Fossati‐Bellani, F., & Beretta, G. (1970) · PubMed · Cited by 278
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., Ferreira-Martins, J., Zheng, H., Hosoda, T., Rota, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.895771 · Cited by 268
Liu, J., Mao, W., Ding, B., & Liang, C.-S. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00407.2008 · Cited by 255
Kang, Y. J., Chen, Y., Yu, A., Voss-McCowan, M., & Epstein, P. N. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119672 · Cited by 253
Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis
Green, P. S., & Leeuwenburgh, C. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00144-8 · Cited by 252
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Kremer, L. C. M., van Dalen, E. C., Offringa, M., & Voûte, P. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf118 · Cited by 249
Javadov, S., Karmazyn, M., & Escobales, N. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153213 · Cited by 248
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel-Sadron, G., & Londos-Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Zhu, W., Soonpaa, M. H., Chen, H., Shen, W., Payne, R. M., Liechty, E. A., Caldwell, R. L., Shou, W., & Field, L. J. (2009) · Circulation · doi:10.1161/circulationaha.108.799700 · Cited by 229
Molecular Basis of Anthracycline-Induced Cardiotoxicity and Its Prevention
Horenstein, M. S., Vander Heide, R. S., & L'Ecuyer, T. J. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3043 · Cited by 228
Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., & Wallace, K. B. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.04.005 · Cited by 227
Self-citationExercise training improves myocardial tolerance to in vivo ischemia-reperfusion in the rat
Powers, S. K., Demirel, H. A., Vincent, H. K., Coombes, J. S., Naito, H., Hamilton, K. L., Shanely, R. A., & Jessup, J. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.275.5.r1468 · Cited by 225
Maejima, Y., Adachi, S., Ito, H., Hirao, K., & Isobe, M. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2007.00358.x · Cited by 224
Clinical Evaluation of Adriamycin, a New Antitumour Antibiotic
Bonadonna, G., Monfardini, S., de Lena, M., & Fossati-Bellani, F. (1969) · BMJ · doi:10.1136/bmj.3.5669.503 · Cited by 220
Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J., & Walker, U. A. (2003) · Circulation · doi:10.1161/01.cir.0000093196.59829.df · Cited by 219
Kuznetsov, A. V., Margreiter, R., Amberger, A., Saks, V., & Grimm, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.002 · Cited by 207
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
Danesi, R., Fogli, S., Gennari, A., Conte, P., & Del Tacca, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00004 · Cited by 203
Structure of the adriamycin-cardiolipin complex
Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R., & Ruysschaert, J.-M. (1990) · Biophysical Chemistry · doi:10.1016/0301-4622(90)80012-v · Cited by 200
Antioxidants, Tissue Damage, and Endurance in Trained and Untrained Young Male Rats
Venditti, P., & Di Meo, S. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0283 · Cited by 199
Ueno, M., Kakinuma, Y., Yuhki, K.-I., Murakoshi, N., Iemitsu, M., Miyauchi, T., & Yamaguchi, I. (2006) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0050980 · Cited by 189
Kim, Y., Ma, A.-G., Kitta, K., Fitch, S. N., Ikeda, T., Ihara, Y., Simon, A. R., Evans, T., & Suzuki, Y. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.368 · Cited by 188
Andrieu‐Abadie, N., Jaffrézou, J., Hatem, S., Laurent, G., Levade, T., & Mercadier, J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.12.1501 · Cited by 182
Fan, G.-C., Zhou, X., Wang, X., Song, G., Qian, J., Nicolaou, P., Chen, G., Ren, X., & Kranias, E. G. (2008) · Circulation Research · doi:10.1161/circresaha.108.182832 · Cited by 178
The neglected significance of “antioxidative stress”
Poljsak, B., & Milisav, I. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/480895 · Cited by 177
Lu, L., Wu, W., Yan, J., Li, X., Yu, H., & Yu, X. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.01.043 · Cited by 175
Yoshida, M., Shiojima, I., Ikeda, H., & Komuro, I. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.07.024 · Cited by 174
Carvedilol Protects against Doxorubicin-Induced Mitochondrial Cardiomyopathy
Santos, D. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9532 · Cited by 174
Kawaguchi, T., Takemura, G., Kanamori, H., Takeyama, T., Watanabe, T., Morishita, K., Ogino, A., Tsujimoto, A., Goto, K., Maruyama, R., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs282 · Cited by 172
Doxorubicin Inactivates Myocardial Cytochrome c Oxidase in Rats: Cardioprotection by Mito-Q
Chandran, K., Aggarwal, D., Migrino, R. Q., Joseph, J., McAllister, D., Konorev, E. A., Antholine, W. E., Zielonka, J., Srinivasan, S., Avadhani, N. G., et al. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2008.10.042 · Cited by 170
Vleet, J. F. V., Ferrans, V. J., & Weirich, W. E. (1980) · PubMed · Cited by 169
Anthracycline-Induced Cardiotoxicity
Ferreira, A., Matsubara, L., & Matsubara, B. (2008) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152508785909474 · Cited by 168
The molecular composition of the mitochondrial permeability transition pore
Baines, C. P. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.02.007 · Cited by 164
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R., & Chua, B. H. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00759.2003 · Cited by 162
Brown, D. A., Lynch, J. M., Armstrong, C. J., Caruso, N. M., Ehlers, L. B., Johnson, M. S., & Moore, R. L. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.081323 · Cited by 162
Spallarossa, P., Altieri, P., Aloi, C., Garibaldi, S., Barisione, C., Ghigliotti, G., Fugazza, G., Barsotti, A., & Brunelli, C. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00068.2009 · Cited by 160
Ascensão, A., Magalhães, J., Soares, J. M. C., Ferreira, R., Neuparth, M. J., Marques, F., Oliveira, P. J., & Duarte, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01249.2004 · Cited by 160
Self-citationSerrano, J., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00011-0 · Cited by 159
Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., SCHAUB, M. C., Wallimann, T., & Schlattner, U. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2004 · Cited by 159
Melatonin as an effective protector against doxorubicin-induced cardiotoxicity
Liu, X., Chen, Z., Chua, C. C., Ma, Y.-S., Youngberg, G. A., Hamdy, R., & Chua, B. H. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01023.2001 · Cited by 159
Marcillat, O., Zhang, Y., & Davies, K. J. A. (1989) · Biochemical Journal · doi:10.1042/bj2590181 · Cited by 149
Sardão, V. A., Oliveira, P. J., Holy, J. M., Oliveira, C. R., & Wallace, K. B. (2008) · Cell Biology and Toxicology · doi:10.1007/s10565-008-9070-1 · Cited by 136
Self-citationDrug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Pereira, G. C., Silva, A. M., Diogo, C. V., Carvalho, F. S., Monteiro, P. F., & Oliveira, P. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904812 · Cited by 136
Self-citationMitochondrial DNA is a direct target of anti-cancer anthracycline drugs
Ashley, N., & Poulton, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.059 · Cited by 134
Lebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A. (2005) · The Journal of Pathology · doi:10.1002/path.1863 · Cited by 133
Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy
Carvalho, R. A., Sousa, R. P. B., Cadete, V. J. J., Lopaschuk, G. D., Palmeira, C. M., Bjork, J. A., & Wallace, K. B. (2010) · Toxicology · doi:10.1016/j.tox.2010.01.019 · Cited by 131
Self-citationCardiotoxicity of doxorubicin and other anthracycline derivatives
Jain, D. (2000) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2000.103324 · Cited by 131
Acute exercise can improve cardioprotection without increasing heat shock protein content
Taylor, R. P., Harris, M. B., & Starnes, J. W. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.276.3.h1098 · Cited by 131
Jang, Y. M., Kendaiah, S., Drew, B., Phillips, T., Selman, C., Julian, D. A., & Leeuwenburgh, C. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.053 · Cited by 126
Gratia, S., Kay, L., Potenza, L., Seffouh, A., Novel-Chaté, V., Schnebelen, C., Sestili, P., Schlattner, U., & Tokarska-Schlattner, M. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs134 · Cited by 125
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff, B. B., & Herman, E. H. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0023-3 · Cited by 123
Hrelia, S., Fiorentini, D., Maraldi, T., Angeloni, C., Bordoni, A., Biagi, P. L., & Hakim, G. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00612-0 · Cited by 120
Exposure to Anthracyclines During Childhood Causes Cardiac Injury
Lipshultz, S. E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.019 · Cited by 120
Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice
Ascensão, A. A. M. R., Magalhães, J., Soares, J. M., Ferreira, R. M., Neuparth, M. J., Marques, F., de Oliveira, J. J. F., & Duarte, J. A. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.11.004 · Cited by 118
The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin
Hasinoff, B. B., Patel, D., & Wu, X. (2003) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2003.08.005 · Cited by 115
Acute Exercise Protects Against Doxorubicin Cardiotoxicity
Wonders, K. Y., Hydock, D. S., Schneider, C. M., & Hayward, R. (2008) · Integrative Cancer Therapies · doi:10.1177/1534735408322848 · Cited by 110
Parker, M. A., King, V., & Howard, K. P. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00371-6 · Cited by 107
Pathology of late-onset anthracycline cardiomyopathy
Bernaba, B. N., Chan, J. B., Lai, C. K., & Fishbein, M. C. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.07.004 · Cited by 106
Ascensão, A., Lumini-Oliveira, J., Machado, N. G., Ferreira, R. M., Gonçalves, I. O., Moreira, A. C., Marques, F., Sardão, V. A., Oliveira, P. J., & Magalhães, J. (2011) · Clinical Science · doi:10.1042/cs20100254 · Cited by 103
Self-citationProtective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats
Matsui, H., Morishima, I., Numaguchi, Y., Toki, Y., Okumura, K., & Hayakawa, T. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00362-8 · Cited by 103
A Deletion of Mitochondrial DNA in Murine Doxorubicin-Induced Cardiotoxicity
Adachi, K., Fujiura, Y., Mayumi, F., Nozuhara, A., Sugiu, Y., Sakanashi, T., Hidaka, T., & Toshima, H. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2135 · Cited by 103
Berthiaume, J. M., Oliveira, P. J., Fariss, M. W., & Wallace, K. B. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:257 · Cited by 101
Self-citationPreferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin
Palmeira, C. M., Serrano, J. A., Kuehl, D. W., et al. (1997) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(97)00055-8 · Cited by 100
Exercise Training Attenuates Acute Doxorubicin-Induced Cardiac Dysfunction
Chicco, A. J., Schneider, C. M., & Hayward, R. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000199682.43448.2d · Cited by 99
Berthiaume, J. M., & Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0026-0 · Cited by 99
Xiong, Y., Liu, X., Lee, C.-P., Chua, B. H. L., & Ho, Y.-S. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.02.024 · Cited by 96
Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin
Tokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2006) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2005.08.007 · Cited by 94
Oliveira, P. J., & Wallace, K. B. (2006) · Toxicology · doi:10.1016/j.tox.2005.12.009 · Cited by 94
Self-citationModulation of sarcoplasmic reticulum Ca2+ release by glycolysis in cat atrial myocytes
Kockskämper, J., Zima, A. V., & Blatter, L. A. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.078782 · Cited by 91
Sardão, V. A., Oliveira, P. J., Holy, J. M., Oliveira, C. R., & Wallace, K. B. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0932-x · Cited by 91
Self-citationSehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E., & Demant, E. J. F. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90514-w · Cited by 91
Yamaoka‐Tojo, M., Yamaguchi, S., Suzuki, T., Okuyama, M., Nitobe, J., Nakamura, N., Mitsui, Y., & Tomoike, H. (2000) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2000.1132 · Cited by 90
Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation
Noguchi, N., Nishino, K., & Niki, E. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00417-7 · Cited by 89
Mechanism of inhibition of mitochondrial enzymatic complex I–III by adriamycin derivatives
Goormaghtigh, E., Huart, P., Brasseur, R., & Ruysschaert, J. (1986) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(86)90406-2 · Cited by 89
Age dependence of the early-phase pharmacokinetics of doxorubicin.
Robert, J., & Hoerni, B. (1983) · PubMed · Cited by 85
Demant, E. J. F., & Jensen, P. K. (1983) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1983.tb07397.x · Cited by 83
Dimitrakis, P., Romay-Ogando, M.-I., Timolati, F., Suter, T. M., & Zuppinger, C. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1475-8 · Cited by 82
Ramires, P. R., & Ji, L. L. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.2.h679 · Cited by 82
Exercise improves postischemic function in aging hearts
Starnes, J. W., Taylor, R. P., & Park, Y. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00952.2002 · Cited by 80
Birth Defects and Childhood Cancer in Offspring of Survivors of Childhood Cancer
Green, D. M., Fiorello, A., Zevon, M. A., Hall, B., & Seigelstein, N. (1997) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1997.02170410053007 · Cited by 80
Doxorubicin in experimental and clinical heart failure
Christiansen, S., & Autschbach, R. (2006) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2006.06.024 · Cited by 78
Cardoso, S., Santos, R. X., Carvalho, C., Correia, S. C., Pereira, G. C., Pereira, S. P., Oliveira, P. J., Santos, M. S., Proença, T., & Moreira, P. I. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.08.008 · Cited by 77
Self-citationAmlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes
Yamanaka, S., Tatsumi, T., Shiraishi, J., Mano, A., Keira, N., Matoba, S., Asayama, J., Fushiki, S., Fliss, H., & Nakagawa, M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02935-2 · Cited by 76
Chen, K., Xu, X., Kobayashi, S., Timm, D. J., Jepperson, T. N., & Liang, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225805 · Cited by 75
Tokarska-Schlattner, M., Wallimann, T., & Schlattner, U. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.516 · Cited by 75
Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9c2 cells
Chua, C. C., Liu, X., Gao, J., Hamdy, R. C., & Chua, B. H. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01138.2005 · Cited by 74
Velez, J. M., Miriyala, S., Nithipongvanitch, R., Noel, T. J., Plabplueng, C. D., Oberley, T. D., Jungsuwadee, P., Remmen, H. V., Vore, M. E., & Clair, D. K. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018005 · Cited by 73
Zhang, X., Peng, X., Yu, W., Hou, S., Zhao, Y., Zhang, Z., Huang, X., & Wu, K. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.001 · Cited by 73
Early changes in myocardial antioxidant enzymes in rats treated with adriamycin
Li, T., Danelisen, I., & Singal, P. K. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1014862912783 · Cited by 69
Is there a threshold intensity for aerobic training in cardiac patients?
SWAIN, D. P., & FRANKLIN, B. A. (2002) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200207000-00003 · Cited by 67
Cardiovascular toxicity with cancer chemotherapy
Frishman, W. H., Yee, H. C. M., Keefe, D. L., Sung, H. M., Liu, L. L., Einzig, A. I., & Dutcher, J. P. (1997) · Current Problems in Cancer · doi:10.1016/s0147-0272(97)80001-3 · Cited by 67
The effects of α-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice
Mimnaugh, E. G., Siddik, Z. H., Drew, R., Sikic, B. I., & Gram, T. E. (1979) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(79)90284-9 · Cited by 66
Demonstration of the existence of an organo‐specific NADH dehydrogenase in heart mitochondria
Nohl, H. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb13649.x · Cited by 61
Free radical production from normal and adriamycin-treated rat cardiac sarcosomes
Thornalley, P. J., & Dodd, N. J. F. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90262-x · Cited by 61
Beneficial Effects of Exercise on Muscle Mitochondrial Function in Diabetes Mellitus
Lumini‐Oliveira, J., Magalhães, J., Oliveira, P. J., & Ascensão, A. A. M. R. (2008) · Sports Medicine · doi:10.2165/00007256-200838090-00003 · Cited by 61
Self-citationAscensão, A. A. M. R., Oliveira, P. J., & Magalhães, J. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.05.060 · Cited by 60
Self-citationL-carnitine attenuates doxorubicin-induced lipid peroxidation in rats
Luo, X., Reichetzer, B., Trines, J., Benson, L. N., & Lehotay, D. C. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00303-7 · Cited by 60
Pregnancy outcome in women treated with doxorubicin for childhood cancer
Bar, J., Davidi, O., Goshen, Y., et al. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00837-8 · Cited by 59
Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture
DeAtley, S. M., Aksenov, M. Y., Aksenova, M. V., Jordan, B., Carney, J. M., & Butterfield, D. A. (1999) · Toxicology · doi:10.1016/s0300-483x(99)00039-6 · Cited by 58
Jirkovský, E., Popelová, O., Staňková, P., Jirkovská, A., Hroch, M., Hašková, P., Doleželová, E., Mičuda, S., Adamcová, M., Šimůnek, T., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198358 · Cited by 57
Feridooni, T., Hotchkiss, A. G., Remley-Carr, S., Saga, Y., & Pasumarthi, K. B. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022801 · Cited by 57
Iron is not involved in oxidative stress‐mediated cytotoxicity of doxorubicin and bleomycin
Mertlíková‐Kaiserová, H., den Hartog, G. J. M., Šimůnek, T., Schröterová, L., Kvasničková, E., & Bast, A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706930 · Cited by 56
Richard, C., Ghibu, S., Delemasure, S., Guilland, J.-C., Rosiers, C. D., Zeller, M., Cottin, Y., Rochette, L., & Vergely, C. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185892 · Cited by 56
Monti, E., Prosperi, E., Supino, R., et al. (1995) · PubMed · Cited by 55
Exercise training mitigates anthracycline‐induced chronic cardiotoxicity in a juvenile rat model
Hayward, R., Lien, C., Jensen, B. T., Hydock, D. S., & Schneider, C. M. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23392 · Cited by 54
Sayed‐Ahmed, M. M., Al‐Shabanah, O. A., Hafez, M. M., Aleisa, A. M., & Al-Rejaie, S. S. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.05.002 · Cited by 54
Mitra, M. S., Donthamsetty, S., White, B., Latendresse, J. R., & Mehendale, H. M. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.07.018 · Cited by 52
Oliveira, P. J., Santos, M. S., & Wallace, K. B. (2006) · Biochemistry (Moscow) · doi:10.1134/s000629790602012x · Cited by 49
Self-citationTokarska-Schlattner, M., Lucchinetti, E., Zaugg, M., Kay, L., Gratia, S., Guzun, R., Saks, V. A., & Schlattner, U. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00360.2009 · Cited by 49
New iron chelators in anthracycline-induced cardiotoxicity
Mertlíková‐Kaiserová, H., Šimůnek, T., Štěrba, M., den Hartog, G. J. M., Schröterová, L., Popelová, O., Geršl, V., Kvasničková, E., & Bast, A. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0020-6 · Cited by 47
Induction of caspase-independent apoptosis in H9c2 cardiomyocytes by adriamycin treatment
Youn, H., Kim, H., Jeon, M.-H., Lee, J.-H., Seo, Y.-J., Lee, J. H., & Lee, J. H. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-2541-2 · Cited by 47
Yoon, H.-R., Hong, Y. M., Boriack, R. L., et al. (2003) · Pediatric Research · doi:10.1203/01.pdr.0000057988.62605.13 · Cited by 43
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer
Bárdi, E., Bobok, I., Oláh, A. V., et al. (2007) · Pathology & Oncology Research · doi:10.1007/bf02893506 · Cited by 43
Lebrecht, D., Kirschner, J., Geist, A., Haberstroh, J., & Walker, U. A. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.06.006 · Cited by 42
Voest, E. E., van Acker, S. A. B. E., van der Vijgh, W. J. F., van Asbeck, B. S., & Bast, A. (1994) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1994.1136 · Cited by 42
Kunisada, K. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00506-5 · Cited by 41
Carvedilol Inhibits the Exogenous NADH Dehydrogenase in Rat Heart Mitochondria
Oliveira, P. J., Santos, D. L., & Moreno, A. J. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1624 · Cited by 37
Self-citationPereira, G. C., Pereira, S. P., Pereira, C. V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038867 · Cited by 36
Taylor, R. P., Olsen, M. E., & Starnes, J. W. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00094.2006 · Cited by 36
Exercise and cardiac oxidative stress.
Ascensão, A. A. M. R., Magalhães, J., Soares, J., de Oliveira, J. A. C., & Duarte, J. A. (2003) · PubMed · Cited by 35
Pifithrin‐α promotes p53‐mediated apoptosis in JB6 cells
Kaji, A., Zhang, Y., Nomura, M., Bode, A. M., Ma, W., She, Q., & Dong, Z. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10130 · Cited by 31
Hepatic and cardiac carnitine palmitoyltransferase activity
Brady, L. J., & Brady, P. S. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90320-0 · Cited by 26
Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats
Todorova, V. K., Kaufmann, Y., Hennings, L. J., & Klimberg, V. S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1165-8 · Cited by 19
Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals
Villani, F., Beretta, G., & Guindani, A. (1979) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254740 · Cited by 17
Sugiyama, S., Satoh, H., Nomura, N., Watanabe, H. K., & Hayashi, H. (2001) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007261322878 · Cited by 15
Machado, N. G., Baldeiras, I., Pereira, G. C., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.027 · Cited by 15
Oliveira, P. J., Rolo, A. P., Sardão, V. A., Monteiro, P. F., Gonçalves, L. M. M., Providência, L. A., Palmeira, C. M., & Moreno, A. J. (2004) · PubMed · Cited by 13
Self-citationSugiyama, S., Yamada, K., Hayakawa, M., et al. (1995) · PubMed · Cited by 10
Cited by
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701
Molecular mechanism of doxorubicin-induced cardiomyopathy – An update
Renu, K., V.G., A., P.B., T. P., & Arunachalam, S. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.043 · Cited by 588
Zhao, L., Qi, Y., Xu, L., Tao, X., Han, X., Yin, L., & Peng, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.013 · Cited by 344
Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
Metadata
- Authors
- Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2013-03-11
- Volume
- 34
- Issue
- 1
- Pages
- 106-135
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2122189144
- Cited by
- 569
- References
- 190
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.